*For medical professionals only
Talk about the frontier of gastrointestinal tumors and create a new future of diagnosis and treatment
On June 29, 2024, Shanghai ushered in the grand convening of the mid-year meeting of the Young Expert Committee of the Chinese Society of Clinical Oncology (CSCO). The conference was hosted by the Chinese Society of Clinical Oncology and co-organized by the Young Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG). Among them, the gastrointestinal tumor sub-venue brought together top experts and young talents in the field of gastrointestinal cancer from all over the country to discuss the latest progress and future development direction of gastrointestinal cancer diagnosis and treatment.
Photos of the venue
Chairman's Speech: Diagnosis and Treatment of Gastrointestinal Tumors: The Collision of Thinking and Practice
The presidium members of the conference included Professor Zhang Xiaotian from Peking University Cancer Hospital, Professor Chen Gong from Sun Yat-sen University Cancer Center, Professor Ding Peirong from Sun Yat-sen University Cancer Center, Professor Liu Jing from Shengjing Hospital Affiliated to China Medical University, Professor Wei Jia from Drum Tower Hospital Affiliated to Nanjing University School of Medicine, and Professor Chen Xiaofeng from Jiangsu Provincial People's Hospital.
At the beginning of the conference, Professor Zhang Xiaotian, Professor Chen Gong and Professor Liu Jing successively made opening speeches, and the three chairmen of the conference, on behalf of the members of the presidium, extended a warm welcome to the experts and scholars attending the meeting, and profoundly elaborated on the theme and importance of the conference. They emphasized that this conference is not only a platform to display research results, but also an important opportunity to stimulate innovative thinking and promote academic exchanges, encourage young experts to innovate in academic research, and jointly promote progress in the field of gastrointestinal cancer diagnosis and treatment.
Professor Zhang Xiaotian
Professor Chen Gong
Professor Liu Jing
Exploration of immunological and anti-angiogenic therapies
The first part of the conference was chaired by Prof. Jing Liu and Prof. Xiaofeng Chen. Professor Zheng Yanan from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, first shared the exploration and practice of surgical treatment of gastric cancer in the era of immunity. He introduced in detail the application prospects and challenges of immunotherapy in the surgical treatment of gastric cancer, emphasizing the importance of multidisciplinary collaboration. Professor Cheng pointed out that with the rapid development of immunotherapy, surgical treatment strategies also need to be constantly adjusted to maximise the benefits for patients.
Prof. Chen Xiaofeng (left) and Prof. Liu Jing (right)
Professor Zheng Yanan
Immediately afterwards, Professor Deng Wei from Beijing Friendship Hospital affiliated to Capital Medical University brought a special report on the application of anti-angiogenic drugs combined with immunotherapy in advanced gastric cancer. She noted that the combination of anti-angiogenic drugs and immunotherapy is expected to provide a new treatment option for patients with advanced gastric cancer, and demonstrated good data from multiple blockbuster clinical trials demonstrating the efficacy and safety of this combination treatment regimen.
Professor Deng Wei
In the discussion session, Professor Song Na from the First Affiliated Hospital of China Medical University, Professor Sun Li from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, and Professor Li Wenhua from Fudan University Cancer Hospital had in-depth discussions and exchanges, and discussed practical problems and solutions in clinical practice. Experts agreed that future research should focus more on the development of individualized treatment plans to improve treatment outcomes.
Professor Song Na
Professor Sun Li
Professor Li Wenhua
At the end of the first part, Professor Chen Xiaofeng introduced and introduced a special session - "We Voice - Qinglan Society Launching Ceremony". Professor Chen Xiaofeng first gave a detailed introduction to the original intention of the establishment of the project and the project plan, elaborated on the efforts of the Qinglan Society project to train young doctors, and invited young doctors to actively participate in it, looking forward to jointly contributing to the standardization of gastrointestinal tumor diagnosis and treatment and improving the clinical diagnosis and treatment and scientific research ability of young doctors.
The launching ceremony of "Qinglan Society".
An in-depth interpretation of the 2024 ASCO gastric cancer research progress
The second part of the conference was chaired by Professor Wei Jia from the Drum Tower Hospital affiliated to Nanjing University School of Medicine and Professor He Wan from Shenzhen People's Hospital. Professor Cao Yanshuo from Peking University Cancer Hospital and Professor Wang Yizhuo from the First Hospital of Jilin University respectively gave a detailed interpretation of the research on the treatment of perioperative gastric cancer and advanced or metastatic gastric cancer presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Prof. Ho Wan (left) and Prof. Wei Jia (right)
Professor Cao Yanshuo focused on the new strategies for the perioperative treatment of gastric cancer, including neoadjuvant therapy and postoperative adjuvant therapy, emphasized the importance of immunotherapy in perioperative treatment, and looked forward to the future exploration direction of individualized and precision therapy.
Professor Cao Yanshuo
Professor Wang Yizhuo analyzed the latest research results in the treatment of advanced or metastatic gastric cancer in detail, including HER2, CLDN18.2 and VEGFR, and explained the application of new targeted drugs and immunotherapy. Professor Wang Yizhuo also pointed out that with the deepening of molecular biology research, more targets have been discovered, the division of gastric cancer population has become more and more refined, and the treatment methods and programs have become more precise and individualized, which has brought new dawn and hope to patients with advanced gastric cancer.
Professor Wang Yizhuo
In the ensuing discussion, Professor Xing Rui from Shengjing Hospital affiliated to China Medical University and Professor Su Meng from Liaoning Provincial Cancer Hospital shared their clinical experiences and insights on immunotherapy for perioperative and advanced gastric cancer. Professor He Wan answered and summarized the questions in the discussion, and briefly interpreted the future exploration direction of first-line treatment based on her own clinical experience.
Professor Xing Rui
Professor Su Meng
Interpreting the latest breakthroughs in the treatment of colorectal cancer in ASCO
The third part was chaired by Professor Xue Junli from Shanghai East Hospital and Professor Dong Chao from the First Affiliated Hospital of Kunming Medical University in Yunnan Province. Professor Xia Fan from Fudan University Cancer Hospital and Professor Zhang Jianwei from the Sixth Affiliated Hospital of Sun Yat-sen University respectively gave a wonderful report on the research progress of the treatment of locally advanced colorectal cancer and advanced colorectal cancer in ASCO in 2024.
Prof. Dong Chao (left), Prof. Xue Junyu (right)
In addition, Professor Xia Fan affirmed the value of research and exploration on organ preservation of bowel cancer, and shared the latest progress in the whole process of neoadjuvant therapy (TNT) for rectal cancer. Professor Zhang Jianwei focused on the new progress in the treatment of advanced colorectal cancer, and studied and interpreted it from three parts: colorectal cancer liver metastasis (CRLM), first-line treatment of metastatic colorectal cancer and precision treatment of metastatic colorectal cancer. Professor Zhang Jianwei pointed out that with the deepening of molecular biology research, new drugs targeting targets such as KRAS G12C and BRAF have also emerged, which has greatly enriched the choices of patients with advanced colorectal cancer.
Prof. Xia Bon
Professor Zhang Jianwei
During the discussion session, Professor Han Peng from the Affiliated Cancer Hospital of Harbin Medical University, Professor Wang Deqiang from the Affiliated Hospital of Jiangsu University, and Professor Meng Lingjun from the China-Japan Friendship Hospital of Jilin University had a heated discussion and deeply discussed the hot topics in the treatment of bowel cancer. Experts agreed that future research should pay more attention to the optimal design and consideration of research protocols, pursue more effective and safe treatment regimens, improve the overall treatment effect and better improve the quality of life of patients.
Professor Han Peng
Professor Wang Deqiang
Professor Meng Lingjun
Focus on translational therapies and innovative therapies
The fourth part was co-chaired by Professor Xue Junli from Shanghai East Hospital and Professor Deng Ting from Tianjin Cancer Hospital. Professor Lu Yingying from Xijing Hospital of Air Force Medical University, Professor Qi Changsong from Peking University Cancer Hospital and Professor Liang Tingting from the First Hospital of Jilin University respectively introduced the research progress of conversion therapy, CAR-T therapy and bispecific antibody therapy for gastrointestinal tumors.
Prof. Xiao (left), Prof. Xue Jun-yu (right)
In her sharing, Professor Lu introduced the current problems faced in the diagnosis and treatment of gastrointestinal tumors, introduced the latest progress in the research of translational therapy of gastrointestinal tumors, and emphasized the importance of close integration of basic research and clinical application.
Professor Lo Ming-ying
Professor Qi Changsong introduced in detail the R&D status and application prospects of cell therapy in gastrointestinal tumors, and especially demonstrated the efficacy and safety data of a number of CAR-T treatment regimens related to different targets, proving the efficacy and safety of CAR-T cell therapy in gastrointestinal tumors.
Professor Qi Changsong
Professor Liang Tingting focused on the types of bispecific antibodies and related mechanisms in the diagnosis and treatment of gastrointestinal tumors, and interpreted the latest progress in a number of bispecific antibody related research, and the development and emergence of many new bispecific antibodies are expected to provide new treatment options for patients with gastrointestinal tumors.
Professor Liang Tingting
In the discussion session, Professor Li Wei from the First Affiliated Hospital of Soochow University, Professor Huang Xiaobing from Union Hospital of Fujian Medical University, and Professor Chen Ying from the First Affiliated Hospital of China Medical University discussed and shared their research experience and clinical practice experience. Experts agreed that future research should be based on clinical practice, pay more attention to the clinical transformation and practical application of new treatment modalities, improve the accessibility of the program, and better improve the survival and prognosis of patients.
Professor Li Wei
Professor Huang Xiaobing
Professor Chen Ying
Frontier exploration of colorectal cancer immunotherapy and new options for chemotherapy
The final part of the meeting was chaired by Professor Shi Yan from Shanghai Seventh People's Hospital and Professor Qiu Haibo from Sun Yat-sen University Cancer Center. Professor Yu Yiyi from Zhongshan Hospital Affiliated to Fudan University and Professor Liu Ke from the Second Affiliated Hospital of Naval Medical University respectively conducted in-depth discussions on new chemotherapy options in the era of immunotherapy for MSI-H/dMMR colorectal cancer and gastric cancer.
Prof. Shi Yan (left), Prof. Qiu Haibo (right)
Professor Yu Yiyi introduced the immunotherapy strategy of MSI-H/dMMR colorectal cancer in detail, made an in-depth interpretation from the current status of immunotherapy, the progress of immunotherapy and future prospects, and emphasized the importance of precision therapy in the treatment of MSI-H/dMMR colorectal cancer.
Professor Yu Yiyi
Professor Ke Liu focused on the new options of chemotherapy in the era of immunotherapy for gastric cancer, demonstrated the clinical trial data of a variety of new chemotherapy regimens, strongly proved the effectiveness and safety of new chemotherapy regimens, and put forward new thinking and directions for the innovation and progress of chemotherapy methods and regimens.
Professor Ke Liu
In the final discussion session, Professor Han Lu from the General Hospital of the People's Liberation Army of Chinese and Professor Zhao Liying from the Nanfang Hospital of Southern Medical University had a warm exchange with everyone, fully affirming the rich clinical experience and cutting-edge research results of colorectal cancer experts in China. Experts agreed that future research should pay more attention to the clinical application and promotion of new treatment modalities to benefit more patients.
Professor Han Lu
Professor Zhao Liying
Inherit the past and create the future together! The meeting was successfully concluded
At the end of the meeting, the experts of the presidium of the conference made a wonderful summary. They expressed their gratitude to the experts for their wonderful reports and heated discussions, and looked forward to the future development direction of gastrointestinal cancer treatment. The Presidium of the conference emphasized the importance of cooperation and exchange, and encouraged young experts to continue their efforts to jointly promote progress in the field of gastrointestinal oncology.
So far, the gastrointestinal tumor branch of the 2024 CSCO Youth Committee Mid-year Meeting has come to a successful conclusion with warm applause. This conference not only showcased the latest research results and clinical practice experience in the field of gastrointestinal cancer, but also provided a platform for young experts to exchange and learn. In the future, we look forward to more innovations and breakthroughs to bring more hope and gospel to patients with gastrointestinal tumors.
Exciting information is waiting for you
* This article is only for the purpose of providing scientific information to medical professionals and does not represent the views of this platform